"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients
Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Sep 24, 2024
Trial Information
Current as of May 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The "Smart Family Doctor" trial is looking at how a digital health management tool, powered by artificial intelligence, can help improve the control of high blood pressure, diabetes, and cholesterol levels in patients who have recently undergone coronary artery bypass grafting (CABG) surgery. The study will involve around 536 participants from 5 to 10 hospitals and aims to see if this technology can make it easier for patients to manage their health after surgery.
To participate in this trial, you need to be at least 18 years old and have had CABG surgery. You should also have a history of high blood pressure, diabetes, or high cholesterol. If your blood pressure is above certain levels, your blood sugar level (measured by HbA1c) is too high, or your cholesterol levels are not in the healthy range, you may qualify. Participants will need to use a smartphone and provide informed consent to join. This trial is not yet recruiting, so there is no need to take action just yet, but it offers an exciting opportunity to potentially improve health outcomes for patients in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years.
- • History of CABG surgery with history of hypertension, diabetes, and dyslipidemia.
- * At least one of the following criteria is meet:
- • Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg
- • HbA1c no less than 7%
- • LDL-C no less than 1.8 mmol/L
- • Use of a smartphone.
- • Signed informed consent.
- Exclusion Criteria:
- • History of heart failure or severe arrhythmias.
- • Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency.
- • Pregnancy, lactation, or plans for pregnancy within the next year.
- • Cognitive, communication impairments, or limitations in daily activities.
About China National Center For Cardiovascular Diseases
The China National Center for Cardiovascular Diseases (NCCD) is a leading research and clinical trial sponsor dedicated to advancing cardiovascular health in China and globally. As a prominent institution, NCCD focuses on innovative research, clinical management, and education in cardiovascular medicine. The center plays a crucial role in conducting rigorous clinical trials aimed at developing new therapies and improving patient outcomes for cardiovascular diseases. Through collaboration with national and international partners, NCCD is committed to enhancing the understanding of cardiovascular conditions and translating research findings into practical applications for improved healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Xin Yuan, PhD
Principal Investigator
Chinese Academy of Medical Sciences, Fuwai Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported